drugset / Trial / NCT03667482
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of cabozantinib, at different doses, in combination with cetuximab to find out what effects, if any, this combined treatment has on people with HNSCC.
Timeline
- Start
- 2018-09-07
- Primary completion
- 2024-07-17
- Completion
- 2024-07-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 20 mg | Oral |
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |
| Background | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |